CRISPR Therapeutics AG: Casgevy Pediatric Expansion From Age 12 Down to Age 2

研报英文原文证据摘录

CRISPR Therapeutics AG: Casgevy Pediatric Expansion From Age 12 Down to Age 2

Update

July 2, 2026 12:35 PM GMT

Morgan Stanley & Co. LLCMCRISPR Therapeutics AG | North America Maxwell Skor

Equity Analyst

Casgevy Pediatric Expansion Maxwell.Skor@morganstanley.comSelena Zhang +1 212 761-4804

Research Associate

Selena.Zhang1@morganstanley.com +1 212 761-1017

From Age 12 Down to Age 2

CRISPR Therapeutics AG (CRSP.O, CRSP US)

Biotechnology | United States of America

Key Takeaways Stock Rating Equal-weight

Industry View Attractive

Casgevy received a supplemental approval for patients aged 2 years and older, Price target $60.00

previously approved for patients aged 12 years and older. Shr price, close (Jul 1, 2026) $55.62

Mkt cap, curr (mm) $5,361

We see a meaningful opportunity for earlier treatment of patients prior to 52-Week Range $78.48-44.12

damage to the vascular system and a driver for center activation.

Casgevy receives a supplemental approval for patients aged 2 years and older.

The FDA issued a supplemental approval to Vertex Pharmaceuticals (covered by

Terence Flynn) for Casgevy for patients aged 2 years and older with either sickle cell

disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent

β thalassemia (TDT) (press release), previously approved for patients aged 12 years

and older. Vertex submitted for supplemental approval of Casgevy in ages 5 to <12

with Commissioner’s National Priority Voucher in the US. While pediatric expansion

was expected, the extrapolation to the younger pediatric age of 2+ years from the

expected 5+ years based on product characteristics and clinical study data was an

incremental surprise. As we laid out in our initiation (see our note HERE), we expect